MarketCapExport financials
Legend Biotech Corporation (LEGN)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Legend Biotech Corporation Income Statement 2025-2011 | LEGN
Brief overview of financial performance at Legend Biotech Corporation
This overview is based on financial performance over the past five years. Revenue reported by Legend Biotech Corporation was $60 million at the beginning of the period and $627 million at the end. The cumulative result was +945.8%, corresponding to roughly 59.9% per year. Revenue growth reflects a pronounced phase of business expansion.
The operating result measured by EBITDA moved from $0 to −$310 million, or . At the operating-margin level, the figure shifted from 0% to −49.3%. The margin contraction indicates weaker operating efficiency.
The final result was −$133 million initially and −$177 million in the final year. The negative result deepened, showing weaker final efficiency.
Summary assessment
The financial trajectory is weak and requires a cautious interpretation. The strongest signals are revenue expansion. Caution is warranted because of a narrow EBITDA buffer, pressure on operating profitability and a weaker final result. The next reporting periods will show whether revenue, margins, and final profitability can strengthen.
Annual Income Statement Legend Biotech Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
6.91 B | 11.7 B | 19.8 B | 21.1 B | 11.2 B | 3.21 B | - | - | 38.8 M | - | - | - | - | - | - |
Shares |
369 M | 366 M | 352 M | 318 M | 282 M | 118 M | - | - | 259 M | - | - | - | - | - | - |
Historical Prices |
18.8 | 32 | 56.1 | 66.4 | 39.6 | 27.2 | - | - | - | - | - | - | - | - | - |
Net Income |
-297 M | -177 M | -518 M | -446 M | -386 M | -303 M | -133 M | -2.78 M | - | - | - | - | - | - | - |
Revenue |
- | 627 M | 285 M | 117 M | 68.8 M | 75 M | 60 M | 49.1 M | - | - | - | - | - | - | - |
Cost of Revenue |
397 M | 216 M | 144 M | 65.4 M | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
- | 411 M | 141 M | 51.6 M | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-136 M | -310 M | -528 M | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
-136 M | -310 M | -528 M | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Expenses |
- | 720 M | 669 M | 51.6 M | - | - | 193 M | 64.2 M | - | - | - | - | - | - | - |
General and Administrative Expenses |
- | - | - | - | - | 23.1 M | 6.75 M | 2.77 M | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement Legend Biotech Corporation
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
369 M | 369 M | 368 M | 368 M | 434 M | 367 M | 365 M | 364 M | 3.87 M | 7.51 M | 341 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
-297 M | -39.7 M | -125 M | -101 M | 26.3 M | -125 M | -18.2 M | -59.8 M | -145 M | -62.2 M | -311 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
- | 272 M | 255 M | 195 M | 187 M | 160 M | 187 M | 94 M | 79.5 M | 96 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
397 M | 113 M | 94.9 M | 69.5 M | 69.4 M | 52.5 M | 45.4 M | 49.1 M | 32.4 M | 43.5 M | 68.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
- | 159 M | 160 M | 126 M | 117 M | 108 M | 141 M | 44.9 M | 47 M | 52.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-136 M | -43.5 M | - | - | -79.3 M | -70.4 M | - | - | -528 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
-136 M | -43.5 M | - | - | -79.3 M | -70.4 M | - | - | -528 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Expenses |
- | 203 M | 160 M | 126 M | 196 M | 178 M | 141 M | 44.9 M | 575 M | 52.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company Legend Biotech Corporation (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Russia
USA
Canada
Niderland
Israel
Schweiz
Australia
Britain
